erowe on PROD1PC63 with NOTICES

Federal Register / Vol. 74, No. 110 / Wednesday, June 10, 2009 / Notices 27551 

FEDERAL MARITIME COMMISSION Intermediary licenses have been of Ocean Transportation Intermediaries, 

reissued by the Federal Maritime 46 CFR Part 515. Ocean Transportation Intermediary Commission pursuant to section 19 of License Reissuances the Shipping Act of 1984 (46 U.S.C. 

Notice is hereby given that the Chapter 409) and the regulations of the

Commission pertaining to the licensing following Ocean Transportation 

License No. Name/address Date reissued 

001593F ............................................................ 

013172N ........................................................... 

Robertson Forwarding Co., Inc., 4469 NW 97th Ave., Miami, FL 33178 ......... 

Yung Hoon Kim, dba Conex International, 20695 South Western Ave., Suite 

136, Torrance, CA 90501. 

May 10, 2009. 

May 6, 2009. 

Sandra L. Kusumoto, 

Director, Bureau of Certification and 

Licensing. 

[FR Doc. E9–13639 Filed 6–9–09; 8:45 am] 

BILLING CODE 6730–01–P 

FEDERAL MARITIME COMMISSION 

Ocean Transportation Intermediary 

License Revocations 

The Federal Maritime Commission 

hereby gives notice that the following 

Ocean Transportation Intermediary 

licenses have been revoked pursuant to 

section 19 of the Shipping Act of 1984 

(46 U.S.C. Chapter 409) and the 

regulations of the Commission 

pertaining to the licensing of Ocean 

Transportation Intermediaries, 46 CFR 

Part 515, effective on the corresponding 

date shown below: 

License Number: 000692F. 

Name: A. R. Savage & Son, Inc. 

Address: 701 Harbour Post Dr., 

Tampa, FL 33602. 

Date Revoked: May 27, 2009. 

Reason: Failed to maintain a valid 

bond. 

License Number: 017799NF. 

Name: Alpha Freight & Transport 

International, Inc. 

Address: 3508 NW 114th Ave., Ste. 

205, Doral, FL 33178. 

Date Revoked: May 27, 2009. 

Reason: Surrendered license 

voluntarily. 

License Number: 018583NF. 

Name: Astron Distribution, Inc. 

Address: 349 NW 16th Street, Ste. 

107, Belle Glade, FL 33430. 

Date Revoked: May 27, 2009. 

Reason: Failed to maintain valid 

bonds. 

License Number: 018878N. 

Name: BTL Group, Inc. Dba E–World 

Cargo, Inc. 

Address: 7910 SO. 3500 E., Ste. B, Salt 

Lake, UT 84121. 

Date Revoked: May 6, 2009. 

Reason: Surrendered license 

voluntarily. 

License Number: 021167N. 

Name: Cargonline (USA) Inc. 

Address: 245 E. Main Street, Ste. 112, 

Alhambra, CA 91801. 

Date Revoked: May 21, 2009. 

Reason: Failed to maintain a valid 

bond. 

License Number: 004084F. 

Name: Glory Express, Inc. 

Address: 17420 S. Avalon Blvd., Ste. 

202, Carson, CA 90746. 

Date Revoked: May 22, 2009. 

Reason: Failed to maintain a valid 

bond. 

License Number: 017911N. 

Name: Kasy Logistics Co., Ltd. 

Address: 355 S. Lemon Ave., #N, 

Walnut, CA 91789. 

Date Revoked: May 29, 2009. 

Reason: Surrendered license 

voluntarily. 

License Number: 016503NF. 

Name: Lukini Shipping Inc. 

Address: One Cross Island Plaza, Ste. 

203d, Rosedale, NY 11422. 

Date Revoked: May 27, 2009. 

Reason: Failed to maintain valid 

bonds. 

License Number: 002145F. 

Name: Henry Juliusburger DBA 

Nautique-Worldwide. 

Address: 55 New Montgomery St., 

Ste. 514, San Francisco, CA 94105. 

Date Revoked: May 22, 2009. 

Reason: Failed to maintain a valid 

bond. 

License Number: 013797N. 

Name: Kenneth Bola Obatusin DBA 

Global Freightways (USA), Ltd. 

Address: 10630 Riggs Hill Rd., Bldg. 

R, Jessup, MD 20794. 

Date Revoked: May 29, 2009. 

Reason: Failed to maintain a valid 

bond. 

License Number: 016484N. 

Name: Kenny International USA, Inc. 

DBA KTL (USA) International. 

Address: 145–18 156th Street, Rm. #1, 

Jamaica, NY 11434. 

Date Revoked: April 6, 2009. 

Reason: Surrendered license 

voluntarily. 

License Number: 020066N. 

Name: Manila Forwarders 

Corporation. 

Address: 8241 Backlick Rd., Ste. B, 

Lorton, VA 22079. 

Date Revoked: May 29, 2009. 

Reason: Failed to maintain a valid 

bond. 

License Number: 000334F. 

Name: Perryman Mojonier Company. 

Address: 9720 S. La Cienega Blvd., 

Inglewood, CA 90301. 

Date Revoked: May 29, 2009. 

Reason: Failed to maintain a valid 

bond. 

Sandra L. Kusumoto, 

Director, Bureau of Certification and 

Licensing. 

[FR Doc. E9–13651 Filed 6–9–09; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institute for Occupational 

Safety and Health; Decision To 

Evaluate a Petition To Designate a 

Class of Employees for the Norton 

Company in Worcester, MA, To Be 

Included in the Special Exposure 

Cohort 

AGENCY: National Institute for 

Occupational Safety and Health 

(NIOSH), Department of Health and 

Human Services (HHS). 

ACTION: Notice. 

SUMMARY: HHS gives notice as required 

by 42 CFR 83.12(e) of a decision to 

evaluate a petition to designate a class 

of employees for the Norton Company 

in Worcester, Massachusetts, to be 

included in the Special Exposure Cohort 

under the Energy Employees 

Occupational Illness Compensation 

Program Act of 2000. The initial 

proposed definition for the class being 

evaluated, subject to revision as 

warranted by the evaluation, is as 

follows: 

Facility: Norton Company. 

Location: Worcester, Massachusetts. 

Job Titles and/or Job Duties: All 

Atomic Weapons Employer employees. 

Period of Employment: January 1, 

1945 through December 31, 1957. 

erowe on PROD1PC63 with NOTICES

27552 Federal Register / Vol. 74, No. 110 / Wednesday, June 10, 2009 / Notices 

FOR FURTHER INFORMATION CONTACT: 

Larry Elliott, Director, Office of 

Compensation Analysis and Support, 

National Institute for Occupational 

Safety and Health (NIOSH), 4676 

Columbia Parkway, MS C–46, 

Cincinnati, OH 45226, Telephone 513– 

533–6800 (this is not a toll-free 

number). Information requests can also 

be submitted by e-mail to 

OCAS@CDC.GOV. 

Christine M. Branche, 

Acting Director, National Institute for 

Occupational Safety and Health. 

[FR Doc. E9–13662 Filed 6–9–09; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the National Coordinator for 

Health Information Technology; HIT 

Standards Committee Meeting 

ACTION: Announcement of meeting. 

SUMMARY: This notice announces the 

second meeting of the HIT Standards 

Committee in accordance with the 

Federal Advisory Committee Act (Pub. 

L. No. 92–463, 5 U.S.C., App.). 


DATES: June 23, 2009, from 9 a.m. to 12 


p.m. [Eastern] 


ADDRESSES: The Omni Shoreham Hotel, 


2500 Calvert Street, NW., Washington, 


DC 20008, Diplomat Ballroom. 


FOR FURTHER INFORMATION CONTACT: 

http://healthit.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

The meeting will include 

presentations from the HIT Standards 

Committee Workgroups. The meeting is 

a Web-based meeting with 

teleconference dial-in. If you have 

special needs for the meeting, please 

contact (202) 690–7151. 

Judith Sparrow, 

Office of Programs and Coordination, Office 

of the National Coordinator for Health 

Information Technology. 

[FR Doc. E9–13630 Filed 6–9–09; 8:45 am] 

BILLING CODE 4150–45–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Proposed Collection; Comment 

Request; Investigator Registration and 

Financial Disclosure for Investigational 

Trials in Cancer Treatment (NCI) 

SUMMARY: In compliance with the 

requirement of Section 3506(c)(2)(A) of 

the Paperwork Reduction Act of 1995, 

for opportunity for public comment on 

proposed data collection projects, the 

National Cancer Institute, the National 

Cancer Institute (NIH) will publish 

periodic summaries to the Office of 

Management and Budget (OMB) for 

review and approval. 

Proposed Collection: Title: 

Investigator Registration and Financial 

Disclosure for Investigational Trials in 

Cancer Treatment (NCI). Type of 

Information Collection Request: Existing 

Collection in use without an OMB 

Control Number. Need and Use of 

Information Collection: Food and Drug 

Administration (FDA) regulations 

require sponsors to obtain information 

from the investigator before permitting 

the investigator to begin participation in 

investigational studies. The National 

TABLE 1—ESTIMATES OF ANNUAL BURDEN 

Cancer Institute (NCI), as a sponsor of 

investigational drug trials, has the 

responsibility to assure the FDA that 

investigators in its clinical trials 

program are qualified by training and 

experience as appropriate experts to 

investigate the drug. In order to fulfill 

these requirements, a standard 

Statement of Investigator (FDA Form 

1572 modified), Supplemental 

Investigator Data Form, Financial 

Disclosure Form and Curriculum vitae 

(CV) are required. The data obtained 

from these forms allows the NCI to 

evaluate the qualifications of the 

investigator, identify appropriate 

personnel to receive shipment of 

investigational agent, ensure supplies 

are not diverted for inappropriate 

protocol or patient use and identify 

financial conflicts of interest. 

Comparisons are done with the 

intention of ensuring protocol, patient 

safety and drug compliance for patient 

and drug compliance for patient safety 

and protections. 

Frequency of Response: Annually. 

Affected Public: Public sector, 

businesses other for-profit. Federal 

agencies or employees, non-profit 

institutions and a very small number of 

private practice physicians. 

Type of Respondents: Health care 

investigators. The annual reporting 

burden is limited to those physicians 

who choose to participate in NCI 

sponsored investigational trials to 

identify new medicinal agents to treat 

and relieve those patients suffering from 

cancer. It is estimated that the total 

annual burden will be 8,564 hours, and 

include 17,128 investigators, for this 

project (see Table 1). 

Type of respondents Form Number of respondents 

Frequency of 

response Average time per response Total hour burden 

Investigators and Designee ... 

Totals .............................. 

Statement of Investigator ..... 

Supplemental Investigator .... 

Financial Disclosure ............. 

............................................... 

17,128 

17,128 

17,128 

17,128 

1 

1 

1 

........................ 

0.25 (15 minutes) ................. 

0.167 (10 minutes) ............... 

0.083 (5 minutes) ................. 

............................................... 

4,282 

2,855 

1,427 

8,564 

There is no capital, operating or 

maintenance costs to report. 

Request for Comments: Written 

comments and/or suggestions from the 

public and affected agencies are invited 

on one or more of the following points: 

(1) Whether the proposed collection of 

information is necessary for the proper 

performance of the function of the 

agency, including whether the 

information will have practical utility; 

(2) The accuracy of the agency’s 

estimate of the burden of the proposed 

collection of information; including the 

validity of the methodology and 

assumptions used; (3) Ways to enhance 

the quality, utility and clarity of the 

information to be collected; and (4) 

Ways to minimize the burden of the 

collection of information on those who 

are to respond, including the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the data collection plans and 

instruments, contact Charles L. Hall, Jr., 

Chief, Pharmaceutical Management 

Branch, Cancer Therapy Evaluation 

Program, Division of the Cancer 

Treatment and Diagnosis, and Centers, 

National Cancer Institute, Executive 

Plaza North, Room 7148, 9000 Rockville 

Pike, Bethesda, MD 20892 or call nontoll-free number 301–496–5725 or E-